These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 30219843)

  • 21. Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection.
    Gay CL; Neo DT; Devanathan AS; Kuruc JD; McGee KS; Schmitz JL; Sebastian J; Shaheen NJ; Ferrari G; McKellar M; Fiscus SA; Hicks CB; Robertson K; Kashuba ADM; Eron JJ; Margolis DM
    AIDS; 2020 Nov; 34(13):1923-1931. PubMed ID: 32773474
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Depression and diagnosis of neurocognitive impairment in HIV-positive patients.
    Pinheiro CA; Souza LD; Motta JV; Kelbert EF; Souza MS; Martins CS; Coelho FM; Pinheiro KA; Pinheiro RT
    Braz J Med Biol Res; 2016 Sep; 49(10):e5344. PubMed ID: 27626305
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Trajectories of Depressive Symptoms, Neurocognitive Function, and Viral Suppression With Antiretroviral Therapy Among Youth With HIV Over 36 months.
    Kohn JN; Loop MS; Kim-Chang JJ; Garvie PA; Sleasman JW; Fischer B; Rendina HJ; Woods SP; Nichols SL; Hong S
    J Acquir Immune Defic Syndr; 2021 Jun; 87(2):851-859. PubMed ID: 33587499
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Profile of HIV/AIDS Neurocognitive Impairment among HIV Positive Patients in North Central Nigeria.
    Osaigbovo OG; Ugoya S; Ogunniyi A
    West Afr J Med; 2015; 34(3):179-184. PubMed ID: 28276043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is the use of the QPC cognitive complaints questionnaire relevant for the screening strategy of HIV-Associated neurocognitive disorders?
    Zaegel-Faucher O; Laroche H; Tixier M; Morisseau V; Obry-Roguet V; Poizot-Martin I
    AIDS Care; 2021 Mar; 33(3):389-397. PubMed ID: 32279542
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Development of a neurocognitive test battery for HIV-associated neurocognitive disorder (HAND) screening: suggested solutions for resource-limited clinical settings.
    Chan LG; Ho MJ; Lin YC; Ong Y; Wong CS
    AIDS Res Ther; 2019 Apr; 16(1):9. PubMed ID: 30987670
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Neurocognitive functioning in antiretroviral therapy-naïve youth with behaviorally acquired human immunodeficiency virus.
    Nichols SL; Bethel J; Garvie PA; Patton DE; Thornton S; Kapogiannis BG; Ren W; Major-Wilson H; Puga A; Woods SP
    J Adolesc Health; 2013 Dec; 53(6):763-71. PubMed ID: 23972941
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study: baseline participant profile.
    Métral M; Darling K; Locatelli I; Nadin I; Santos G; Brugger P; Kovari H; Cusini A; Gutbrod K; Tarr PE; Calmy A; Lecompte TD; Assal F; Monsch A; Kunze U; Stoeckle M; Schwind M; Schmid P; Pignatti R; Di Benedetto C; Du Pasquier R; Cavassini M; ;
    HIV Med; 2020 Jan; 21(1):30-42. PubMed ID: 31589807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
    Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
    J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Correlates of the HIV-associated neurocognitive disorders among adults living with HIV in Dodoma region, central Tanzania: A cross-sectional study.
    Nyundo AA
    PLoS One; 2023; 18(5):e0285761. PubMed ID: 37228133
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimal monitoring strategies for guiding when to switch first-line antiretroviral therapy regimens for treatment failure in adults and adolescents living with HIV in low-resource settings.
    Chang LW; Harris J; Humphreys E
    Cochrane Database Syst Rev; 2010 Apr; (4):CD008494. PubMed ID: 20393969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiretroviral Therapy Intensification for Neurocognitive Impairment in Human Immunodeficiency Virus.
    Letendre SL; Chen H; McKhann A; Roa J; Vecchio A; Daar ES; Berzins B; Hunt PW; Marra CM; Campbell TB; Coombs RW; Ma Q; Swaminathan S; Macatangay BJC; Morse GD; Miller T; Rusin D; Greninger AL; Ha B; Alston-Smith B; Robertson K; Paul R; Spudich S;
    Clin Infect Dis; 2023 Sep; 77(6):866-874. PubMed ID: 37183889
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of HIV and Atiretroviral Therapy on Neurocognitive Outcomes Among School-Aged Children.
    Brahmbhatt H; Boivin M; Ssempijja V; Kagaayi J; Kigozi G; Serwadda D; Violari A; Gray RH
    J Acquir Immune Defic Syndr; 2017 May; 75(1):1-8. PubMed ID: 28169874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.
    La Rosa AM; Harrison LJ; Taiwo B; Wallis CL; Zheng L; Kim P; Kumarasamy N; Hosseinipour MC; Jarocki B; Mellors JW; Collier AC;
    Lancet HIV; 2016 Jun; 3(6):e247-58. PubMed ID: 27240787
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive and sustained effects of highly active antiretroviral therapy on HIV-1-associated neurocognitive impairment.
    Tozzi V; Balestra P; Galgani S; Narciso P; Ferri F; Sebastiani G; D'Amato C; Affricano C; Pigorini F; Pau FM; De Felici A; Benedetto A
    AIDS; 1999 Oct; 13(14):1889-97. PubMed ID: 10513647
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Meta-Analytic Review of the Effect of Antiretroviral Therapy on Neurocognitive Outcomes in Adults Living with HIV-1 in Low-and Middle-Income Countries.
    Michael HU; Youbi E; Ohadoma SC; Ramlall S; Oosthuizen F; Polyakova M
    Neuropsychol Rev; 2022 Dec; 32(4):828-854. PubMed ID: 34757490
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Frequency and Correlates of Subjective Cognitive Impairment in HIV Disease.
    Sheppard DP; Woods SP; Massman PJ; Gilbert PE
    AIDS Behav; 2019 Mar; 23(3):617-626. PubMed ID: 30311103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Moderate to severe HIV-associated neurocognitive impairment: A randomized placebo-controlled trial of lithium.
    Decloedt EH; Freeman C; Howells F; Casson-Crook M; Lesosky M; Koutsilieri E; Lovestone S; Maartens G; Joska JA
    Medicine (Baltimore); 2016 Nov; 95(46):e5401. PubMed ID: 27861379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of HIV Subtype and Antiretroviral Therapy on HIV-Associated Neurocognitive Disorder Stage in Rakai, Uganda.
    Sacktor N; Saylor D; Nakigozi G; Nakasujja N; Robertson K; Grabowski MK; Kisakye A; Batte J; Mayanja R; Anok A; Gray RH; Wawer MJ
    J Acquir Immune Defic Syndr; 2019 Jun; 81(2):216-223. PubMed ID: 30865184
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Antiretroviral Therapy on Neurocognitive Outcomes Among People Living with HIV in Low- and Middle-Income Countries (LMICs): A Systematic Review.
    Michael HU; Naidoo S; Mensah KB; Ramlall S; Oosthuizen F
    AIDS Behav; 2021 Feb; 25(2):492-523. PubMed ID: 32851562
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.